Cervical cancer (CAN) is a significant health concern for women worldwide, ranking as one of the most common cancers (Arbyn et al., 2020; WHO, 2020; Aobchey et al., 2022; Wang et al., 2022). As per the World Health Organization (WHO), in 2018, approximately 570,000 women were diagnosed with cervical cancer globally, resulting in roughly 311,000 fatalities (WHO, 2020; Wickramasinghe et al., 2021; Zhang et al., 2022). Furthermore, the WHO projected in 2020 that the annual incidence of new cases of this disease could rise from 570,000 to 700,000 between 2018 and 2030 (WHO, 2020).

The prevalence of this disease is notably higher in low-to middle-income countries, nonetheless, it affects women globally. The number of deaths in low and middle-income countries accounted for an estimated 90% of the 311,000 global fatalities. Consequently, age-standardized incidence rates fluctuate from 75 per 100,000 women in the highest-risk countries to fewer than 10 per 100,000 women in the lowest-risk countries (Bray et al., 2018; WHO, 2020). This disparity underscores the urgency to address cervical cancer, particularly in regions with higher risk factors.

Human papillomavirus (HPV) infection is pivotal in the development of cervical cancer, with nearly 99% of cases associated with high-risk HPV strains (WHO, 2020; Jiang and Wang, 2022). However, other contributing factors such as tobacco use, immunosuppression, malnutrition, and low socioeconomic status are also implicated (ACCP, 2004; Ghebre et al., 2017; Zhang et al., 2020). Persistent infection with various types of HPV is acknowledged as a contributing factor in the progression of cervical intraepithelial neoplasia (CIN) and invasive cervical cancer (ICC). Nevertheless, the complete involvement of HPV in the entire tumorigenic process remains a topic of ongoing debate due to insufficient data (Muñoz, 2000; Castellsagué, 2008; Wheeler, 2013; Kori and Arga, 2018; So et al., 2020; Kang et al., 2021).

Recent literature posits an intriguing hypothesis: microorganisms may play a significant role in malignancies. This theory suggests that there could be unexplored mechanisms during infections where these microscopic entities take a leading role (Parkin, 2006; Godoy-Vitorino et al., 2018).

This perspective necessitates a broader understanding of the microbial world and its potential influence on disease processes. The interplay between HPV and other microorganisms could add another layer of complexity to the etiology of cervical cancer, warranting further investigation. This new viewpoint not only challenges our current knowledge but also paves the way for innovative research directions in cervical cancer pathogenesis.

The detection of microbial diversity, first accomplished in 1677 by Van Leeuwenhoek through microscopic observation, has evolved significantly over time (Wei et al., 2021). In cervical cancer diagnostics, the Papanicolaou smear, a microscopic biopsy image analysis, has traditionally been the primary modality (Long et al., 2017; Kori and Arga, 2018). However, its reliability is debatable due to its dependence on human interpretation (Long et al., 2017). Despite several alternate cervical cancer screening methods proposed over the years such as cytological testing alone, standalone hrHPV testing, and cytological + hrHPV combination testing (co-testing) (Curry et al., 2018; Kim et al., 2018; Terasawa et al., 2022), the 5 years survival rate remains a dismal 66% (Long et al., 2017; Basic et al., 2021; Qu et al., 2021; Hou et al., 2022).

Treatment strategies for cervical cancer, such as surgical resection, radiotherapy, and chemotherapy, are frequently challenged by tumor metastasis and recurrence, complicating disease management (Mallmann and Mallmann, 2016; Vordermark, 2016; Koh et al., 2019; Li et al., 2021). Further, patients often suffer from side effects related to these treatments. This highlights a significant problem: the urgent need for novel, reliable diagnostic methods for cervical cancer that can improve early detection and thereby enhance survival rates (Zhu et al., 2016; Long et al., 2017; Liu et al., 2018; Koh et al., 2019; Han et al., 2021).

The exploration of microbial diversity has been significantly enhanced by advancements in culture technologies. However, due to inherent challenges associated with laboratory culturing procedures, our understanding is not yet exhaustive (Wei et al., 2021). In response to this, techniques centered around molecular sample analysis have emerged within the field of omics, paving the way for a more detailed investigation of microbial diversity (Wei et al., 2021).

The advent of laboratory automation has facilitated the deployment of high-throughput-omics technologies. These sophisticated methodologies enable an in-depth characterization of samples collected from both patients and healthy individuals, thereby expanding our knowledge of microbial ecosystems. One such transformative innovation is next-generation sequencing (NGS). This technique has unlocked the potential to delineate the intricate complexity of microbial communities and human microbiota, providing valuable insights into the influence of the microbiome on human health and disease pathologies (Peterson et al., 2009).

Among the various omic approaches, metagenomics stands out for its ability to divulge specific information about the genomes and genes within a microbial community. It serves as an essential first step in microbiome studies (Marchesi and Ravel, 2015; Aguiar-Pulido et al., 2016). The primary goal of metagenomics is to determine the taxonomic profile of a microbial community, typically involving NGS post-DNA extraction from samples, followed by assembly or mapping to a reference database, and subsequent annotation (Marchesi and Ravel, 2015; Aguiar-Pulido et al., 2016). This method has become particularly prevalent in investigating the microbial composition within the vaginal environment.

The female genital tract serves as a critical ecological niche for human microbiota (Gao et al., 2013), housing Lactobacillus species that contribute to metabolic processes, immunological responses, and overall gynecological health (Kang et al., 2021). Known for probiotic benefits, Lactobacillus species help combat vaginal dysbiosis (Machado et al., 2022; Pacha-Herrera et al., 2022; Rodríguez-Arias et al., 2022). Detailed insights follow in this review’s upcoming sections. There is an emerging body of literature suggesting that alterations in the vaginal microbiota may be linked to cervical cancer (Klein et al., 2020b; Norenhag et al., 2020; So et al., 2020; Tango et al., 2020; Kang et al., 2021; Sims et al., 2021; Wu et al., 2021; Zhou et al., 2021). Furthermore, numerous studies propose that the vaginal microbiota could play a crucial role in defending women against infections such as HPV, vulvovaginal candidiasis, and other sexually transmitted diseases (Liu et al., 2013; Lewis et al., 2017; Arroyo Mühr et al., 2021; Kang et al., 2021). As such, the cervical microbiota could potentially serve as a biomarker for assessing the risk of cancer progression (Mitra et al., 2016a,b; Curty et al., 2019; Arroyo Mühr et al., 2021).

The exploration of the human microbiome has been an exciting journey, with techniques evolving from 16S sequencing (Audirac-Chalifour et al., 2016; Dareng et al., 2016; di Paola et al., 2017; Klein et al., 2020b; Norenhag et al., 2020; So et al., 2020; Tango et al., 2020; Sims et al., 2021; Wu et al., 2021; Zhou et al., 2021), PCR (Norenhag et al., 2020), and microarray (Borgdorff et al., 2014; Norenhag et al., 2020) to cutting-edge methods like RNA-seq (Kori and Arga, 2018; Klein et al., 2020a; Chang et al., 2021) and Whole Genome Shotgun (WGS) (Klein et al., 2020a; Wei et al., 2021). A significant milestone in this journey was the commencement of the Human Microbiome Project (HMP) in 2008, which aimed to map the microbial landscape across various body parts, including the lower genital tract of healthy individuals (Castanheira et al., 2021). From this wealth of research, a startling revelation has emerged: approximately 20% of all fatal cancers are microbially induced (Godoy-Vitorino et al., 2018). Moreover, numerous studies have drawn significant correlations between alterations in the microbiome and cancer phenotypes (Elinav et al., 2019; Poore et al., 2020; Banavar et al., 2021). This underlines the potential of the microbiota as a treasure trove of biomarkers that could revolutionize clinical diagnostics and disease management.

This review is an ambitious endeavor to chart the intricate relationship between the microbiota and cervical cancer progression. We delve into the diverse universe of microorganisms implicated in cervicovaginal dysbiosis, providing an authoritative synthesis of prior research on both CONTROL (healthy) samples and CAN stage. Our goal is to offer an updated perspective on the role of microbiota in cervical cancer progression, thereby filling a crucial gap in the existing literature.

While our analysis provides a comprehensive overview based on the data available at the time of our research, it’s crucial to recognize the fluidity and rapid evolution of scientific knowledge. As such, newer developments may not have been captured. This underscores the need for ongoing research in this field. Therefore, we strongly advocate for broader studies using metagenomics and metatranscriptomics, as these techniques hold immense promise in untangling the intricate role of microbiota in cervical cancer progression. By deepening our understanding of this critical issue, we can pave the way for innovative therapeutic interventions, heralding a new era in women’s health management.

According to the World Health Organization (WHO, 2020), the principal instigator of cervical pre-cancer and squamous cervical cancer is the asymptomatic, persistent or chronic infection with one or more high-risk HPV types. While over 100 HPV types have been identified, only a fraction are associated with cervical cancer. Indeed, two specific types, HPV 16 and 18, are implicated in approximately 70% of all reported cervical cancer cases (Pappa et al., 2018; Cohen et al., 2019; Lin et al., 2019; WHO, 2020). Other high-risk HPV types, such as 31, 33, 45, and 58, are less frequently linked to cervical cancer, with prevalence varying by geographic location. Additionally, low-risk HPV types 6 and 11, although not contributing to cervical cancer, are responsible for most genital warts or condylomas (WHO, 2014).

The role of genetic variation in cervical cancer has been underscored by genome-wide association studies (GWAS). Lin et al. (2019), reported that cervical cancer harbors genetic variations across multiple susceptibility loci (Bahrami et al., 2018; Lin et al., 2019). The viral oncoproteins E6 and E7 appear to play a pivotal role in HPV-infected cervical cancers. Integration of the viral genome into the host DNA results in the upregulation of E6 and E7, leading to the deregulation of key proteins within cellular signaling pathways, including the inhibition of two vital tumor suppressor proteins, p53 and pRb (Oyervides-Muñoz et al., 2018; Lin et al., 2019). The combined effect of E6 and E7 viral proteins triggers the process of immortalization in HPV-infected cells. This precedes the malignant metamorphosis of these cells (Da Silva et al., 2021).

Furthermore, Lau et al. (2015) revealed that DNA tumor virus oncogenes, including E7, can bind to and suppress the cGAS-STING DNA-sensing pathway (Lau et al., 2015; Lin et al., 2019). However, it’s worth noting that not all integrations necessarily rely on the expression of the E6 and E7 oncogenes (Groves and Coleman, 2015; Lin et al., 2019). In addition to these findings, several reports have identified driver mutations in cervical cancer, such as PIK3CA (phosphatidylinositide 3-kinases catalytic subunit α), a central protein in the PI3K pathway, KRAS (Kirsten rat sarcoma viral oncogene homolog), and EGFR (epidermal growth factor receptor) (Lin et al., 2019).

The vaginal microbiota is a critical component of women’s health (Wu et al., 2021). This complex ecosystem, which operates in harmony with the host, provides protective mechanisms against dysbiosis and infection (Klein et al., 2020a). The function of the vaginal mucosa as a barrier against pathogens is facilitated by the interaction of epithelial cells, the immune system, and various microorganisms (Borgdorff et al., 2016; Taddei et al., 2018; Castanheira et al., 2021).

Dominating this ecosystem are Lactobacillus species, which play a significant role in maintaining vaginal health. By producing lactic acid, these bacteria sustain a low pH environment in the cervicovaginal setting, thereby preventing the colonization of harmful opportunistic pathogens, preserving the cervical epithelial barrier, and impeding mucin degradation (Amabebe and Anumba, 2018; Klein et al., 2020a; Norenhag et al., 2020; Salinas et al., 2020; So et al., 2020; Kang et al., 2021; Wu et al., 2021).

However, the composition of the vaginal microbiota is not static. It can be influenced by numerous factors such as genetics, diet, lifestyle, hygiene practices, ethnicity, reproductive age, infections, male factor, usage of antibiotics and contraceptives, sexual activity, physiological status, pregnancy and estrogen levels (Mitra et al., 2016b; Kwasniewski et al., 2018; Wu et al., 2021; Zhou et al., 2021; Baud et al., 2023).

Thanks to new molecular techniques, over 50 microbial species have been identified within the vaginal microbiota, with Lactobacillus spp. being the most prevalent (Norenhag et al., 2020; Wu et al., 2021). Among them, L. crispatus, L. gasseri, L. inners, and L. jensenii are the most commonly found (Wu et al., 2021).

Further research about the vaginal microbiota in healthy women from different ethnic groups (White, Black, Hispanic and Asian) by Ravel et al. (2011) led to the classification of vaginal bacterial communities into five distinct “community state types” (CST). In this classification, Lactobacillus species dominated groups I, II, III, and V. Group IV, on the other hand, was characterized by a diverse set of anaerobic bacteria, including bacteria like Prevotella spp., Streptococcus spp., Dialister spp., Fannyhessea spp. (previously known as Atopobium), Gardnerella spp., Megasphaera spp., Peptoniphilus spp., Sneathia spp., Eggerthella spp., Aerococcus spp., Finegoldia spp., and Mobiluncus spp. These findings were consistent with previous research employing 16S rRNA genes (Srinivasan and Fredricks, 2008; Zhou et al., 2010).

Despite the diversity in bacterial species, a commonality across all CST groups was the presence of lactic acid-producing bacteria, suggesting a conserved function throughout these communities.

The human body is a dynamic ecosystem for a myriad of microbes, collectively known as the microbiome. This microbiome plays a pivotal role in maintaining normal bodily functions, including immune modulation and overall protection (Wei et al., 2021; Zhou et al., 2021). Over time, evidence has emerged highlighting the connection between the microbiome, inflammation, and the development and progression of cancer. According to Zhou et al. (2021) and Wei et al. (2021), disturbances in microbial homeostasis can trigger a cascade of immune responses. Chronic inflammation, a byproduct of such disruptions, is a known carcinogenic factor, heightening the host’s susceptibility to cancer (Zhou et al., 2021).

Given the profound implications of the microbiome on health and disease, specifically cervical cancer, advanced research is warranted. The advent of laboratory automation and high-throughput technologies has revolutionized our understanding of microbiome diversity and its potential impacts (Wei et al., 2021). There is mounting scientific evidence pointing towards a correlation between microbiota and cervical cancer (Castanheira et al., 2021; Kang et al., 2021; Wei et al., 2021; Wu et al., 2021; Zhou et al., 2021).

Cervicitis, or inflammation of the cervix, can stem from various conditions, including microbial infections. Chronic cervicitis has been linked to the development of cervical cancer. Pelvic inflammatory disease (PID) in women is typically triggered by ascending bacterial infections from the cervix to the uterus and fallopian tubes. Bacterial vaginosis (BV), a condition characterized by dysbiosis of cervicovaginal bacteria, is also associated with cervicitis. Notably, the microenvironment fostered by BV is reported to facilitate persistent HPV infection, a known precursor to cervical cancer (Castanheira et al., 2021; Zhou et al., 2021).

Various microorganisms, including Fusobacterium spp., Mycoplasma genitalium, Chlamydia trachomatis, Sneathia spp., Anaerococcus spp., Peptostreptococcus spp., Gardnerella spp., Prevotella spp., Fannyhessea spp., Streptococcus spp., Dialister spp., Megasphaera spp., Peptoniphilus spp., Finegoldia spp., Mobiluncus spp. and Lactobacillus iners have been implicated in the onset of cervical cancer. Interestingly, L. iners is found more frequently in infected women compared to their healthy counterparts. Table 1 provides a detailed overview of these microorganisms and their association with cervical cancer.

As illustrated in Table 1, microorganisms such as Fusobacterium spp., Sneathia spp., Anaerococcus spp., Peptostreptococcus spp., Gardnerella spp., Prevotella spp., Dialister spp., and Megasphaera spp. have been identified as biological markers for cervical cancer (CAN), high-grade squamous intraepithelial lesions (HSIL), and cervical intraepithelial neoplasia (CIN). Conversely, Lactobacillus crispatus, Lactobacillus gasseri, and Lactobacillus jensenii are associated with a decreased risk of infections, including HPV, CIN, and CAN. For an organized overview of this information, please refer to Table 2. This table presents a clear view of the microorganisms found at different disease stages in the vagina. These stages include squamous intraepithelial lesions (SIL)—further divided into low-grade (LSIL) and high-grade (HSIL), cervical intraepithelial neoplasia (CIN), invasive cervical cancer (ICC) or cervical cancer (CAN), and other infections such as pelvic inflammatory disease (PID), HPV, and bacterial vaginitis (BV). Additionally, a column has been included to indicate the microorganisms found in healthy controls (HC). Figure 1 provides a visual representation of the microorganisms present during vaginal inflammation, offering insight into the microbial landscape under these conditions.

Advancements in microbiome research have unveiled new avenues for understanding the root causes of various diseases, including cancer. With the advent of high-throughput technologies such as genomics, transcriptomics, metagenomics, and metatranscriptomics, researchers can now generate an enormous amount of data (Wei et al., 2021). When it comes to cervical cancer, this vast repository of data is meticulously scrutinized to identify potential biomarkers that could transform its diagnosis and prognosis (Norenhag et al., 2020; Han et al., 2021; Kang et al., 2021; Wei et al., 2021; Zhou et al., 2021).

Researchers propose that certain microorganisms serve as beneficial diagnostic markers for cervical cancer or as indicators of infection severity. From the host’s perspective, diverse types of biomarkers (prognostic, predictive, and diagnostic) are being explored to enhance the management of cervical cancer.

High-throughput technologies have paved the way for a deeper exploration of the complex relationship between microbiota and cancer. The capacity to examine the entire microbiome and its intricate micro-ecosystems has led to the identification of specific microbial entities as predictive markers of cancer (Wei et al., 2021). At present, research is primarily centered around four main areas: characterizing microbial diversity and composition, conducting microbial functional analyses, predicting biomarkers, and investigating potential therapeutic applications. However, these areas are still nascent and need to be solidified in clinical practice (Wei et al., 2021).

To fully unravel the correlation between the microbiome and cancer, the consistent use of high-throughput methodologies is deemed necessary. Various studies conducted on the microbiota associated with cervical cancer or cervical disease have reiterated the urgent need for reliable biomarkers to improve the diagnosis of cervical cancer or prevent it. There is a pressing need to devise novel diagnostic strategies incorporating microbiological markers for early detection of cervical cancer in patients (Kang et al., 2021; Sims et al., 2021; Wei et al., 2021; Wu et al., 2021; Zhou et al., 2021).

Several microorganisms, including Fusobacterium spp., Sneathia spp. (S. amnii), Anaerococcus spp., Peptostreptococcus spp., Gardnerella spp. (G. vaginalis), Prevotella spp., Dialister spp., Fannyhessea spp. (F. vaginae), Streptococcus spp., Megasphaera spp., L. crispatus, and L. gasseri (Kori and Arga, 2018; Klein et al., 2020b; Tango et al., 2020), have been suggested as microbiological markers for cervical cancer. The profound implications of these findings for the future of cancer diagnostics underscore the importance of continued research in this promising field.

In an effort to gain deeper insights from the literature, a rigorous process of search was carried out. This process targeted papers that provided accessible information in the NCBI databases. Initially, six potential articles were identified, each providing specific details on vaginal microbiota and cervical health conditions, as illustrated in Table 3. However, upon further exploration for raw data within the NCBI, only four of these articles—marked with asterisk—offered the required information.

Despite the heterogeneity inherent in each database, we undertook a data exploration process to confirm if earlier published data (Ravel et al., 2011; Audirac-Chalifour et al., 2016) aligns with recent publications (So et al., 2020; Kang et al., 2021). It is worth noting that such analyses invariably encounter limitations rooted in the data source, standardization of metadata information, and the procedures employed for sequencing results, among other factors. Nevertheless, our investigation focused on deciphering microbiota patterns across various cervical health conditions.

Regarding the fourth study under scrutiny (Kang et al., 2021), the absence of raw data within the manuscript necessitated a comprehensive reanalysis of the samples provided, guided solely by accession numbers for sequences in the NCBI database. This re-evaluation was executed employing the QIIME-2022.8 pipeline, strictly adhering to the author’s guidelines delineated within their paper. Denoising was performed utilizing DADA2 (Divisive Amplicon Denoising Algorithm 2) (Callahan et al., 2016), and despite Kang et al. (2021) usage of the Silva v138 database, we elected to use the Silva (16S/18S rRNA) (Quast et al., 2013; Yilmaz et al., 2014) database v132. Similar to the authors, the sequences among the reanalyzed samples were rarefied to a sequencing depth of 6,919 reads.

Subsequent to the successful acquisition of data from each of the four papers, the next step was to distill this data, as showed in Table 4. All data abundances were normalized to values ranging from 0 to 1. We successfully compiled a total of 496 samples, encapsulating information pertaining to the type of cervical health condition (CAN, CIN, SIL, and control), the respective study reported, and HPV presence (restricted to CAN and Control samples). The statistical analysis and graphic representation were executed using the R 4.2.1 version.

It is important to highlight that our analysis was conducted within certain constraints. The availability of raw data posed a significant limitation, necessitating the reanalysis of samples in specific instances. Additionally, the low number of articles utilized for our analysis, owing to our commitment to use only freely accessible information, may have affected the comprehensiveness of our study. Despite these challenges, we remained committed to conducting a meticulous and robust exploration of the available data.

According to the previous Table 1, where is presented the microorganisms proposed as microbiological markers in cervical cancer or cervix inflammation, the common bacteria genera found in each one of the four articles that were also mentioned in this table (as potential biomarkers) were: Fusobaterium spp., Sneathia spp., Streptococcus spp., Gardnerella spp., Dialister spp., Megasphaera spp., Peptostreptococcus spp., Peptoniphilus spp., Prevotella spp., Anaerococcus spp., and Lactobacillus spp.

Our findings, as outlined in Table 4, consistently demonstrate the presence of HPV in all documented cases of cervical abnormalities (CAN). To gain a deeper understanding of the bacterial profile associated with CAN, we employed a Venn diagram, as illustrated in Figure 2A. This visualization not only highlights the commonly identified bacteria in CAN cases, but also those observed in control samples. In the context of CAN, our analysis revealed 17 frequently reported bacterial genera: Fusobacterium spp., Sneathia spp., Streptococcus spp., Gardnerella spp., Dialister spp., Megasphaera spp., Peptostreptococcus spp., Peptoniphilus spp., Staphylococcus spp., Campylobacter spp., Parvimonas spp., Prevotella spp., Haemophilus spp., Porphyromonas spp., Anaerococcus spp., Lactobacillus spp., Ureaplasma spp.

To further elucidate the bacterial landscape, an additional Venn diagram was constructed to identify common bacterial genera in control samples from the studies examined (Figure 2A). We observed that 16 genera were common in these samples: Sneathia spp., Streptococcus spp., Gardnerella spp., Dialister spp., Megasphaera spp., Peptoniphilus spp., Staphylococcus spp., Parvimonas spp., Prevotella spp., Porphyromonas spp., Anaerococcus spp., Lactobacillus spp., Ureaplasma spp., Aerococcus spp., Finegoldia spp., Enterococcus spp.

In reference to Table 1, which proposes certain microorganisms as potential microbiological markers for cervical cancer or cervix inflammation, we noted that the following genera were shared between our four selected articles and those suggested as potential biomarkers: Fusobacterium spp., Sneathia spp., Streptococcus spp., Gardnerella spp., Dialister spp., Megasphaera spp., Peptostreptococcus spp., Peptoniphilus spp., Prevotella spp., Anaerococcus spp., and Lactobacillus spp. This overlap may indicate a significant link between these bacterial genera and cervical health disorders.

Simpson’s diversity index, a standard tool for determining alpha diversity, gauges the prevalence of dominant species and inversely correlates with species diversity (Sagar and Sharma, 2012). As illustrated in Figure 2B, our analyses calculated this alpha diversity. The data suggests that as the cervical health condition transitions from Control to SIL, CIN, and CAN, there is an observable increase in microbiota, corroborating previous literature (Klein et al., 2020a; Norenhag et al., 2020; So et al., 2020; Tango et al., 2020; Kang et al., 2021; Sims et al., 2021; Wu et al., 2021; Zhou et al., 2021). Figure 2C presents a similar pattern for HPV (−) samples, where bacterial diversity is comparatively lower than HPV (+) samples. The median value for boxes representing HPV (−) samples is less than 0.25, contrasting with those representing HPV (+) samples. Furthermore, we compiled a list of the top 50 bacterial genera present in HPV (+) and HPV (−) samples across the four studied papers. As depicted in Figure 2D, these bacteria are displayed accordingly.

It is crucial to emphasize that our exploration of the data did not follow the strict guidelines of a meta-analysis or systematic review. This absence of a structured approach may introduce a potential bias in our findings, as we might have overlooked certain studies or emphasized others disproportionately. Also, because we focused on information that’s freely available, there may be some limits to the scope and depth of our analysis. Despite these limitations, we see our work as an initial step in understanding the overall trends in microbiota composition during cervical cancer progression. Our findings should be interpreted with caution, considering the potential biases and methodological constraints. However, we believe our research provides valuable insights that can pave the way for future, more thorough investigations in this crucial area.

The evolution of sequencing methodologies has paved the way for revolutionary advancements in our understanding of microbiomes and associated diseases, including cervical cancer. This progression can be traced through the various technological tools utilized in the quest for comprehension.

In this context, innovative technologies like NextSeq500 (by Illumina) have been employed for parallel DNA and RNA sequencing to comprehensively detect detectable and actively transcribed DNA and RNA microbes in cervical specimens. The results from such studies suggest that the choice of approach (RNA-Seq, DNA-Seq) can influence the number of transcripts obtained. The focus of current research endeavors is to maximize sequence retention in order to amass a wealth of data that could prove beneficial for multiple investigations reliant on database information.

These technological advancements present an exciting opportunity to delve deeper into the intricacies of cervical cancer and its relationship with the microbiota. The wealth of information that these technologies can provide will undoubtedly fuel further research, and potentially lead to breakthroughs in diagnostic and therapeutic strategies.

The analyses conducted herein strongly advocate for continued biomarker exploration and the need for up-to-date data to inform the development of new strategies to combat cervical cancer.

Our review provides a comprehensive overview of the microbiota associated with the progression of cervical cancer and enumerates several microorganisms implicated in cervicovaginal dysbiosis.

Furthermore, we outline the principal discoveries of past research related to the microbiota present during the CONTROL (healthy) and CAN stages, as well as other conditions such as CIN, SIL, HPV (+), and HPV (−). This analysis allowed us to identify promising bacteria frequently reported as biomarkers, suggesting that biomarker identification is a compelling field with potential for numerous research projects.

A consistent presence of HPV was demonstrated in all reported cases of cervical abnormalities. We have identified noteworthy bacterial genera that differ between both CAN and control samples through our investigation. The intersection of these identified bacteria with those suggested as microbiological indicators for cervical health issues in existing research implies a potential connection that needs additional exploration. This understanding of the microbial landscape may provide valuable insights into the pathogenesis of cervical diseases and potentially guide future diagnostic and prevention strategies and treatment plans.

The advent of sequencing techniques has shed new light on our understanding of microbial biomarkers. The rise of this technology holds the promise of facilitating more in-depth studies examining the relationship between cancer and the microbiome. Nevertheless, there is a pressing need for additional research and the standardization of methods for metadata acquisition. This will enhance the scalability of results, ultimately aiming to positively impact the health and wellness of women worldwide.

WF: Conceptualization, Investigation, Methodology, Visualization, Writing – original draft, Writing – review & editing. PA: Conceptualization, Project administration, Supervision, Visualization, Writing – review & editing. LV: Visualization, Writing – review & editing. FM: Investigation, Methodology, Project administration, Supervision, Visualization, Writing – review & editing.